Literature DB >> 23116127

Complement activation in thrombotic microangiopathies.

Shuju Feng1, Michael H Kroll, Leticia Nolasco, Joel Moake, Vahid Afshar-Kharghan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23116127      PMCID： PMC3758746          DOI： 10.1111/bjh.12112

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  10 in total

1.  Eculizumab in the treatment of refractory idiopathic thrombotic thrombocytopenic purpura.

Authors:  John Chapin; Babette Weksler; Cynthia Magro; Jeffrey Laurence
Journal:  Br J Haematol       Date:  2012-03-13       Impact factor: 6.998

Review 2.  Atypical hemolytic uremic syndrome.

Authors:  David Kavanagh; Timothy H J Goodship
Journal:  Curr Opin Hematol       Date:  2010-09       Impact factor: 3.284

3.  Complement activation in thrombotic thrombocytopenic purpura.

Authors:  M Réti; P Farkas; D Csuka; K Rázsó; Á Schlammadinger; M L Udvardy; K Madách; G Domján; C Bereczki; G S Reusz; A J Szabó; Z Prohászka
Journal:  J Thromb Haemost       Date:  2012-05       Impact factor: 5.824

4.  Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies.

Authors:  Maria Piedad Ruiz-Torres; Federica Casiraghi; Miriam Galbusera; Daniela Macconi; Sara Gastoldi; Marta Todeschini; Francesca Porrati; Daniela Belotti; Enrico Maria Pogliani; Marina Noris; Giuseppe Remuzzi
Journal:  Thromb Haemost       Date:  2005-03       Impact factor: 5.249

Review 5.  The molecular biology of thrombotic microangiopathy.

Authors:  H-M Tsai
Journal:  Kidney Int       Date:  2006-05-31       Impact factor: 10.612

6.  von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.

Authors:  M Furlan; R Robles; M Galbusera; G Remuzzi; P A Kyrle; B Brenner; M Krause; I Scharrer; V Aumann; U Mittler; M Solenthaler; B Lämmle
Journal:  N Engl J Med       Date:  1998-11-26       Impact factor: 91.245

7.  Functional analysis in serum from atypical Hemolytic Uremic Syndrome patients reveals impaired protection of host cells associated with mutations in factor H.

Authors:  P Sánchez-Corral; C González-Rubio; S Rodríguez de Córdoba; M López-Trascasa
Journal:  Mol Immunol       Date:  2004-05       Impact factor: 4.407

8.  Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation.

Authors:  Anne-lie Ståhl; Fariba Vaziri-Sani; Stefan Heinen; Ann-Charlotte Kristoffersson; Karl-Henrik Gydell; Reem Raafat; Alberto Gutierrez; Ortraud Beringer; Peter F Zipfel; Diana Karpman
Journal:  Blood       Date:  2008-02-11       Impact factor: 22.113

9.  Complement factor H mutation in familial thrombotic thrombocytopenic purpura with ADAMTS13 deficiency and renal involvement.

Authors:  Marina Noris; Sara Bucchioni; Miriam Galbusera; Roberta Donadelli; Elena Bresin; Federica Castelletti; Jessica Caprioli; Simona Brioschi; Friedrich Scheiflinger; Giuseppe Remuzzi
Journal:  J Am Soc Nephrol       Date:  2005-03-30       Impact factor: 10.121

10.  Hypocomplementemia discloses genetic predisposition to hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: role of factor H abnormalities. Italian Registry of Familial and Recurrent Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura.

Authors:  M Noris; P Ruggenenti; A Perna; S Orisio; J Caprioli; C Skerka; B Vasile; P F Zipfel; G Remuzzi
Journal:  J Am Soc Nephrol       Date:  1999-02       Impact factor: 10.121
  10 in total
  7 in total

1.  von Willebrand factor is a cofactor in complement regulation.

Authors:  Shuju Feng; Xiaowen Liang; Michael H Kroll; Dominic W Chung; Vahid Afshar-Kharghan
Journal:  Blood       Date:  2014-11-13       Impact factor: 22.113

Review 2.  Atypical hemolytic uremic syndrome.

Authors:  Vahid Afshar-Kharghan
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

3.  Von Willebrand factor regulates complement on endothelial cells.

Authors:  Damien G Noone; Magdalena Riedl; Fred G Pluthero; Mackenzie L Bowman; M Kathryn Liszewski; Lily Lu; Yi Quan; Steve Balgobin; Reinhard Schneppenheim; Sonja Schneppenheim; Ulrich Budde; Paula James; John P Atkinson; Nades Palaniyar; Walter H A Kahr; Christoph Licht
Journal:  Kidney Int       Date:  2016-05-25       Impact factor: 10.612

4.  Complement activation associated with ADAMTS13 deficiency in human and murine thrombotic microangiopathy.

Authors:  Ramesh Tati; Ann-Charlotte Kristoffersson; Anne-Lie Ståhl; Johan Rebetz; Li Wang; Christoph Licht; David Motto; Diana Karpman
Journal:  J Immunol       Date:  2013-07-22       Impact factor: 5.422

Review 5.  The interaction between the complement system and hemostatic factors.

Authors:  Selin Oncul; Vahid Afshar-Kharghan
Journal:  Curr Opin Hematol       Date:  2020-09       Impact factor: 3.218

Review 6.  Dissecting the pathophysiology of immune thrombotic thrombocytopenic purpura: interplay between genes and environmental triggers.

Authors:  Johana Hrdinová; Silvia D'Angelo; Nuno A G Graça; Bogac Ercig; Karen Vanhoorelbeke; Agnès Veyradier; Jan Voorberg; Paul Coppo
Journal:  Haematologica       Date:  2018-04-19       Impact factor: 9.941

7.  Assembly and activation of alternative complement components on endothelial cell-anchored ultra-large von Willebrand factor links complement and hemostasis-thrombosis.

Authors:  Nancy A Turner; Joel Moake
Journal:  PLoS One       Date:  2013-03-29       Impact factor: 3.240
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.